Skip to main content

Month: June 2024

Verizon expands network capacity across Alaska

New capacity comes as Verizon marks its tenth anniversary serving Alaska IRVINE, Calif., June 18, 2024 (GLOBE NEWSWIRE) — Verizon recently expanded its network across Alaska, adding additional spectrum at 89 cell sites across the state to increase network capacity by approximately 30 percent. This newly expanded capacity benefits residents, businesses, and visitors in Kenai, Soldotna, Anchor Point, Homer, Seward, Meadow Lake, Denali Park, Two Rivers, and Pleasant Valley. This additional spectrum allows Verizon to provide greater bandwidth and enable higher data speeds for its customers in Alaska. This expansion comes as Verizon celebrates 10 years of delivering the most reliable network experience in Alaska, serving 87 percent of the state’s population. “Verizon is committed to delivering the most reliable network experience and...

Continue reading

RevoluGROUP Canada Inc. Announces Chairman’s Retirement Due to Health Reasons

Vancouver, BC, June 18, 2024 (GLOBE NEWSWIRE) — RevoluGROUP Canada Inc. (TSX-V: REVO), (Frankfurt: IJA2), (Munich: A2PU92) (the “Company”) announces with deep regret that Bernard Lonis, the esteemed Chairman of the Board and Director, has officially stepped down from his roles with the Company, effective June 18, 2024 due to ongoing health concerns. Mr. Lonis initially stepped aside from his duties on May 1st, 2024, as he was admitted in hospital. Lonis said: “Although I am recovering correctly, I am going to listen to this ”wake up call” my body has sent me and change my professional rhythm in all the companies and organizations where I am involved. Including Revolugroup where I will only stay as a major shareholder” Bernard Lonis has been an integral part of RevoluGROUP Canada Inc.’s growth and success over...

Continue reading

SAB Biotherapeutics to Present at the American Diabetes Association 84th Scientific Sessions

MIAMI, June 18, 2024 (GLOBE NEWSWIRE) — SAB Biotherapeutics (Nasdaq: SABS) (the “Company” or “SAB”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it will present a poster at the ADA 84th Scientific Sessions on June 21-24, 2024 in Orlando, Florida. The poster will be presented by SAB’s Senior Program Manager, Eric Sandhurst, Ph.D, and published online in the journal Diabetes®. The American Diabetes Association 84th Scientific Sessions IND-Enabling Assessment of Tolerance and Safety for SAB-142—A First-in-Class Fully Human Anti-thymocyte Immunoglobulin to Delay the Progression of Type 1 Diabetes Date/Time: Sunday, Jun 23, 2024 12:30 PM – 1:30 PM.Location:...

Continue reading

Brazilian Court Orders Tenaris to Pay an Indemnification in Connection with its Acquisition of a Participation in Usiminas in 2012

LUXEMBOURG, June 18, 2024 (GLOBE NEWSWIRE) — Tenaris S.A. (NYSE and Mexico: TS and EXM Italy: TEN) announced today that the Brazilian Superior Court of Justice (SCJ) resolved that Tenaris’s subsidiary Confab and certain subsidiaries of Tenaris’s affiliate Ternium, all of which compose the T/T Group under the Usiminas shareholders agreement, should pay Companhia Siderúrgica Nacional, or CSN, an indemnification in connection with the acquisition by the T/T Group of a participation in Usiminas in January 2012. CSN and various entities affiliated with CSN had filed a lawsuit in Brazil against the T/T Group, alleging that, under applicable Brazilian laws and rules, the acquirers were required to launch a tag-along tender offer to all non-controlling holders of Usiminas ordinary shares for a price per share equal to 80% of the price...

Continue reading

EssilorLuxottica and Diesel announce a ten-year licensing agreement

ESSILORLUXOTTICA AND DIESELANNOUNCE A TEN-YEAR LICENSING AGREEMENT Charenton-le-Pont, France and Milan, Italy (18 June 2024) – EssilorLuxottica and Diesel announced today that they have signed an exclusive license agreement for the design, manufacture, and worldwide distribution of Diesel eyewear. The agreement will be effective immediately until December 31, 2029, with an automatic renewal option of an additional five years. The first collection under the agreement will be available on the market from Q1 2025. The agreement combines Diesel’s bold, fearless and provocative style with the unique craftsmanship, innovation and distribution capabilities of EssilorLuxottica, building on the first collaboration the two companies successfully started in 2022. The new collections will be developed under the leadership of Diesel Creative Director...

Continue reading

Blender Bites Expands Distribution at Walmart Canada with the Addition of Over 100 Stores

VANCOUVER, British Columbia, June 18, 2024 (GLOBE NEWSWIRE) — Blender Bites Limited (the “Company”, “Blender Bites” or “Blender”), (CSE: BITE, FWB: JL4, WKN: A3DMEJ), is thrilled to announce that due to strong sales, the Company has been awarded 100 additional stores at Walmart Canada (the “Retailer”), with Green D-Tox™ and Liquid Sunshine™, specifically, on shelves in over 380 stores out of the total 400 Canadian stores. All eight of the Company’s product SKUs have received additional stores. This growth is particularly significant since, in Canada, it is estimated that 60% of the nation’s population lives within 10 minutes of a Walmart1, substantially enhancing the accessibility and reach of Blender Bites’ products to Canadian consumers. Leading the lineup, Liquid Sunshine™ and Green D-Tox™ will be...

Continue reading

IPSEN – Buy-back programme – Art 5 of MAR – Week 24 – 2024

Aggregated presentation by day and by marketPurchases of own shares from June 10th to 14th  2024             Name of the Issuer Identity code of the Issuer Day of the transaction Identity code of the financial instrument Total daily volume (in number of shares) Daily weighted average purchase price of the shares Market (MIC Code)IPSEN 549300M6SGDPB4Z94P11 10/06/2024 FR0010259150 5 000 122,0351 XPARIPSEN 549300M6SGDPB4Z94P11 11/06/2024 FR0010259150 7 000 122,0734 XPARIPSEN 549300M6SGDPB4Z94P11 12/06/2024 FR0010259150 1 863 123,2022 XPARIPSEN 549300M6SGDPB4Z94P11 13/06/2024 FR0010259150 6 355 123,9046 XPARIPSEN 549300M6SGDPB4Z94P11 13/06/2024 FR0010259150 3 442 123,5264 CEUXIPSEN 549300M6SGDPB4Z94P11 13/06/2024 FR0010259150 203 123,3000 TQEXIPSEN 549300M6SGDPB4Z94P11 14/06/2024 FR0010259150 6 000 120,9126 XPARIPSEN 549300M6SGDPB4Z94P11 14/06/2024 FR0010259150 2...

Continue reading

Combined General Meeting of July 23, 2024 – Conditions for Obtaining the Preparatory Documents

COMBINED GENERAL MEETINGOF JULY 23, 2024 CONDITIONS FOR OBTAINING THE PREPARATORY DOCUMENTS Bernin (Grenoble), France, on June 18, 2024 – Soitec (Euronext Paris), a world leader in the design and manufacturing of innovative semiconductor materials, reminds that the Company’s shareholders are invited to attend the Annual General Meeting to be held on Tuesday July 23, 2024 at 1:30 p.m. (Paris time), at the Company’s registered office located at Parc Technologique des Fontaines, Chemin des Franques, 38190 Bernin, France. The preliminary meeting notice serving as convening notice as provided for in Article R. 225-73 of the French Commercial Code, including the agenda and the draft resolutions to be submitted to the shareholders’ vote during this Annual General Meeting as well as the information on how to attend and vote at the...

Continue reading

Actions to strengthen presence in North Africa : Congress & Surgeons trainings

Press release        Ecully, June 18, 2024 – 6 p.m.Presentation of the KAPHORN system to 200 surgeonsat the SOTCOT Congress in Hammamet The Spineway Group, a specialist in innovative implants for the treatment of severe spine disorders, was represented at the 39th edition of the Tunisian Orthopedic Society (SOTCOT) Congress, held from June 6 to 8 in Hammamet, Tunisia.Dr. Radwan Hilmi (Head of Orthopedics and Traumatology Department at Hôpital Nord Ouest, Villefranche-sur-Saône), co-designer and user of the KAPHORN arthrodesis system, was invited by Pr Chebbi (Professor of Orthopaedic and Spinal Surgery at Centre de traumatologie et des grands brûlés, Tunis) to chair a symposium. In front of an audience of around 200 surgeons, Dr. Hilmi presented the technical features and advantages of Spineway’s KAPHORN system for the treatment of...

Continue reading

Trust Stamp launch AI-powered software on the NayaOne Marketplace

Trust Stamp has launched on the NayaOne Tech Marketplace with AI-powered products to help banks and financial institutions combat fraud, retain customers, and reach a broader user base ATLANTA, GA, June 18, 2024 (GLOBE NEWSWIRE) — Trust Stamp announced that it has launched its proprietary Identity HubTM on the NayaOne Marketplace offering AI-powered software solutions that offer:Advanced Biometric Authentication with liveness and presentation attack detection to combat fraud and enhance security during customer onboarding, account access, and high-risk transactions protecting against identity theft and account takeovers. Robust Identity Verification and KYC including document validation with anti-spoofing checks and synthetic identity detection including identity deduplication. Synthetic Identity Fraud Detection via biometric...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.